These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34560084)

  • 1. Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis.
    Zechner J; Britza SM; Farrington R; Byard RW; Musgrave IF
    Life Sci; 2022 Feb; 291():119975. PubMed ID: 34560084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coenzyme Q10 and statin-related myopathy.
    Drug Ther Bull; 2015 May; 53(5):54-6. PubMed ID: 25977402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
    Osaki Y; Nakagawa Y; Miyahara S; Iwasaki H; Ishii A; Matsuzaka T; Kobayashi K; Yatoh S; Takahashi A; Yahagi N; Suzuki H; Sone H; Ohashi K; Ishibashi S; Yamada N; Shimano H
    Biochem Biophys Res Commun; 2015 Oct; 466(3):536-40. PubMed ID: 26381177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
    Balasubramanian R; Maideen NMP
    Curr Drug Metab; 2021; 22(5):328-341. PubMed ID: 33459228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and myotoxicity: a therapeutic limitation.
    Tiwari A; Bansal V; Chugh A; Mookhtiar K
    Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin-related myotoxicity.
    Fernandes V; Santos MJ; Pérez A
    Endocrinol Nutr; 2016 May; 63(5):239-49. PubMed ID: 27005745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limb girdle muscular disease caused by
    Yogev Y; Shorer Z; Koifman A; Wormser O; Drabkin M; Halperin D; Dolgin V; Proskorovski-Ohayon R; Hadar N; Davidov G; Nudelman H; Zarivach R; Shelef I; Perez Y; Birk OS
    Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2217831120. PubMed ID: 36745799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and assessment of statin-related muscular adverse effects.
    Moßhammer D; Schaeffeler E; Schwab M; Mörike K
    Br J Clin Pharmacol; 2014 Sep; 78(3):454-66. PubMed ID: 25069381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii.
    Hedl M; Rodwell VW
    Protein Sci; 2004 Jun; 13(6):1693-7. PubMed ID: 15152097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA reductase inhibitors and myotoxicity.
    Ucar M; Mjörndal T; Dahlqvist R
    Drug Saf; 2000 Jun; 22(6):441-57. PubMed ID: 10877038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
    Catapano AL
    Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of pharmacogenetic variation on the effects of statins.
    Maggo SD; Kennedy MA; Clark DW
    Drug Saf; 2011 Jan; 34(1):1-19. PubMed ID: 21142270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Statins and mitochondria].
    Broniarek I; Jarmuszkiewicz W
    Postepy Biochem; 2016; 62(2):77-84. PubMed ID: 28132458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
    Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B
    BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health and Disease.
    Hashemi M; Hoshyar R; Ande SR; Chen QM; Solomon C; Zuse A; Naderi M
    Curr Mol Pharmacol; 2017; 10(1):13-26. PubMed ID: 26758949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.